Wednesday, July 8, 2026

pharma · MASH · MASLD · SGMT

Sagimet Biosciences

Sagimet Biosciences is a pharma organization headquartered in San Mateo, USA. It trades on NYSE under ticker SGMT. Primary therapeutic focus areas include MASH, MASLD, Metabolic Syndrome, Non-alcoholic Steatohepatitis, K

155 Bovet Rd, Suite 303, San Mateo, California 94402, US HQ
27 Employees
Public company Type
SGMT · NYSE Ticker
Company details
Status
Public
HQ
155 Bovet Rd, Suite 303, San Mateo, California 94402, US
Employees
27
Programs
12
Drugs
4
Patents
1

Quick answer

Sagimet Biosciences is a pharma organization headquartered in San Mateo, USA. It trades on NYSE under ticker SGMT. Primary therapeutic focus areas include MASH, MASLD, Metabolic Syndrome, Non-alcoholic Steatohepatitis, KRAS Gene Mutation. NovaPharmaNews links 12 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (6), phase 2 (4), phase 3 (2).

Company snapshot

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet

  • 12 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 US patent(s) indexed to this assignee profile.
  • 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sagimet Biosciences. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Sagimet Biosciences.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 12 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Sagimet Biosciences.

  1. Clinical update

    TVB-2640 25 mg (US) — Phase 2

  2. Clinical update

    3-V Bioscience-2640 — Phase 2

  3. Clinical update

    TVB-2640 — Phase 1

  4. Clinical update

    TVB-2640 — Phase 2

  5. Clinical update

    TVB-2640 - 50 mg — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Sagimet Biosciences?

    Sagimet Biosciences is a pharma organization headquartered in San Mateo, USA. It trades on NYSE under ticker SGMT. Primary therapeutic focus areas include MASH, MASLD, Metabolic Syndrome, Non-alcoholic Steatohepatitis, KRAS Gene Mutation. NovaPharmaNews links 12 clinical program(

  • Is Sagimet Biosciences publicly traded?

    Yes. Sagimet Biosciences is listed with ticker SGMT on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Sagimet Biosciences develop or market?

    We link 4 drug profile(s) where Sagimet Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sagimet-biosciences#company-drugs.

  • What are the latest developments for Sagimet Biosciences?

    In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Sagimet Biosciences focus on?

    Sagimet Biosciences focuses on MASH, MASLD, Metabolic Syndrome based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
12
Infectious Disease
4
Oncology
4